An Overview of the Treatment Landscape for Anemia Management in LR-MDS
Thomas W. LeBlanc, MD, MA, discusses how the standard of care (SOC) options for anemia management in patients with low-risk myelodysplastic syndromes (LR-MDS) typically involve erythropoiesis-stimulating agents and transfusion support, with emerging therapies like luspatercept offering new treatment options for better patient outcomes.
Video content above is prompted by the following:
Briefly provide a high-level overview of the SOC options for anemia management in patients with LR-MDS.
Recent Videos
Related Content
